Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $50.11 Consensus Target Price from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine research firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $50.11.

CLDX has been the subject of several recent research reports. Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They set a "buy" rating and a $64.00 target price for the company. The Goldman Sachs Group decreased their target price on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Celldex Therapeutics in a research report on Friday, June 13th. UBS Group decreased their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Morgan Stanley reduced their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th.

Celldex Therapeutics Price Performance

NASDAQ:CLDX traded down $0.56 during mid-day trading on Wednesday, reaching $22.41. The stock had a trading volume of 880,629 shares, compared to its average volume of 967,013. The stock has a 50-day simple moving average of $20.87 and a two-hundred day simple moving average of $21.02. The stock has a market capitalization of $1.49 billion, a PE ratio of -8.30 and a beta of 1.13. Celldex Therapeutics has a 12 month low of $14.40 and a 12 month high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.08 million. Celldex Therapeutics had a negative return on equity of 23.46% and a negative net margin of 2,366.07%. Equities analysts expect that Celldex Therapeutics will post -2.48 EPS for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of large investors have recently added to or reduced their stakes in CLDX. EverSource Wealth Advisors LLC boosted its stake in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 878 shares in the last quarter. GAMMA Investing LLC boosted its stake in Celldex Therapeutics by 6,665.9% during the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock worth $54,000 after acquiring an additional 2,933 shares in the last quarter. Headlands Technologies LLC bought a new stake in Celldex Therapeutics during the fourth quarter worth about $81,000. AlphaQuest LLC raised its holdings in Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after buying an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in Celldex Therapeutics in the fourth quarter worth about $121,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.